SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
| Autor: | Angela Nagel, Kevin Heacock, Samantha Leistman, Nabila Ahmed-Sarwar |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Blood Glucose medicine.medical_specialty medicine.medical_treatment 030209 endocrinology & metabolism 030204 cardiovascular system & hematology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Sodium-Glucose Transporter 2 Diabetes mellitus Internal medicine Empagliflozin Medicine Humans Hypoglycemic Agents Pharmacology (medical) Dapagliflozin Sodium-Glucose Transporter 2 Inhibitors Canagliflozin Glycated Hemoglobin Type 1 diabetes Mesh term business.industry Insulin medicine.disease Endocrinology Diabetes Mellitus Type 1 Treatment Outcome chemistry Insulin dependent diabetes business medicine.drug |
| Zdroj: | The Annals of pharmacotherapy. 51(9) |
| ISSN: | 1542-6270 |
| Popis: | Objective: The purpose of this review is to identify and evaluate disease management of patients with type 1 diabetes mellitus (T1DM) who were treated with a sodium-glucose cotransporter 2 (SGLT-2) inhibitor as an adjunct to insulin therapy. Data Sources: A PubMed (1969 to March 2017) and Ovid (1946 to March 2017) search was performed for articles published utilizing the following MESH terms: canagliflozin, empagliflozin, dapagliflozin, type 1 diabetes mellitus, insulin dependent diabetes, insulin, sodium-glucose transporter 2. There were no limitations placed on publication type. Study Selection and Data Extraction: All English-language articles were evaluated for association of SGLT-2 inhibitors and type 1 diabetes. Further studies were identified by review of pertinent manuscript bibliographies. Data Synthesis: All 3 SGLT-2 inhibitors, when combined with insulin, resulted in an overall reduction of hemoglobin A1C (up to 0.49%), lower total daily insulin doses, and a reduction in weight (up to 2.7 kg). The combination therapy of insulin and SGLT-2 inhibitors also resulted in a lower incidence of hypoglycemia. Study duration varied from 2 to 18 weeks. Conclusion: A review of the identified literature indicated that there is a potential role for the combination of SGLT-2 inhibitors with insulin in T1DM for improving glycemic control without increasing the risk of hypoglycemia. The short duration and small sample sizes limit the ability to fully evaluate the incidences of diabetic ketoacidosis and urogenital infections. The risks associated with this combination of medications require further evaluation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|